TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Lake Street Capital

Research analysts at Lake Street Capital started coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating on the stock.

A number of other research analysts have also weighed in on TLSI. Northland Securities began coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Canaccord Genuity Group lowered their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Trading Up 0.4 %

TLSI stock opened at $5.61 on Thursday. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The business’s 50-day moving average price is $4.79 and its two-hundred day moving average price is $4.74. The firm has a market cap of $171.05 million, a PE ratio of -2.25 and a beta of 0.51.

Insiders Place Their Bets

In related news, major shareholder Equity Ab Frankenius acquired 62,972 shares of TriSalus Life Sciences stock in a transaction on Tuesday, December 17th. The stock was purchased at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Murphy purchased 15,000 shares of the stock in a transaction on Monday, January 27th. The stock was bought at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 124,868 shares of company stock valued at $575,843 over the last 90 days. 32.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the period. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the third quarter worth about $184,000. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences during the third quarter worth about $66,000. Virtu Financial LLC bought a new position in TriSalus Life Sciences in the 3rd quarter valued at about $92,000. Finally, Vestcor Inc acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $108,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.